Extending the Spectrum of Precompetitive Collaboration in Oncology Research - Workshop Summary


Note: Proceedings contain the opinion of the presenters, but do NOT reflect the conclusions of the Health and Medicine Division or the National Academies. Learn more about the differences between Reports and Proceedings.

Although the cost of research and development for new drugs has increased 50-fold since 1970, the success rate for developing new drugs has not improved. In fields such as oncology, in which patients’ survival may depend on new treatments, there is an urgent need to find a more productive way to develop drugs through cooperation among industry, academia, government, and philanthropic organizations. One solution may be increased precompetitive collaboration, or the collaboration among competitors to achieve goals with the potential to benefit everyone, in oncology drug development. Such collaboration would allow institutions to pool resources and expertise for the multidisciplinary research necessary for drug development. In addition, groups working toward similar objectives could learn from one another’s successes and failures, furthering progress toward a shared goal.

The IOM’s National Cancer Policy Forum held a workshop February 9-10, 2010, to explore the benefits and challenges of precompetitive collaboration. Speakers offered lessons learned and best practices as well as steps to increase collaboration in oncology drug development. This document summarizes the workshop.